DNA-PKcs-mediated transcriptional regulation of TOP2B drives chemoresistance in acute myeloid leukemia
Journal of Cell Science · 2024
DOI: 10.1242/jcs.261931 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cell Science, 2024. Verfasst von Saket V Mishra und 6 weiteren Autor:innen. Beteiligte Einrichtung: Shilpee Dutt Laboratory, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Navi Mumbai 410210, India. Hauptthemen laut MEDLINE: DNA-Activated Protein Kinase, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 65 Literaturangaben. Gefördert von: Department of Biotechnology, Ministry of Science and Technology, India, Department of Atomic Energy, Government of India, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre.
Abstract (Originalsprache)
Anthracyclines, topoisomerase II enzyme poisons that cause DNA damage, are the mainstay of acute myeloid leukemia (AML) treatment. However, acquired resistance to anthracyclines leads to relapse, which currently lacks effective treatment and is the cause of poor survival in individuals with AML. Therefore, the identification of the mechanisms underlying anthracycline resistance remains an unmet clinical need. Here, using patient-derived primary cultures and clinically relevant cellular models that recapitulate acquired anthracycline resistance in AML, we have found that GCN5 (also known as KAT2A) mediates transcriptional upregulation of DNA-dependent protein kinase catalytic subunit (DNA-PKcs) in AML relapse, independently of the DNA-damage response. We demonstrate that anthracyclines fail to induce DNA damage in resistant cells, owing to the loss of expression of their target enzyme, TOP2B; this was caused by DNA-PKcs directly binding to its promoter upstream region as a transcriptional repressor. Importantly, DNA-PKcs kinase activity inhibition re-sensitized AML relapse primary cultures and cells resistant to mitoxantrone, and abrogated their tumorigenic potential in a xenograft mouse model. Taken together, our findings identify a GCN5–DNA-PKcs–TOP2B transcriptional regulatory axis as the mechanism underlying anthracycline resistance, and demonstrate the therapeutic potential of DNA-PKcs inhibition to re-sensitize resistant AML relapse cells to anthracycline.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shilpee Dutt Laboratory, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Navi Mumbai 410210, India.
- Homi Bhabha National Institute, Training School Complex, Anushakti Nagar, Mumbai 400085, India.
- Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Centre, Mumbai 400012, India.
- Cell and Tumor Biology Group, Advanced Centre for Treatment Research Education in Cancer (ACTREC), Tata Memorial Centre, Navi Mumbai 410210, India.
ORCID-Profile: Saket V Mishra, Shilpee Dutt
Förderung
- Department of Biotechnology, Ministry of Science and Technology, India
- Department of Atomic Energy, Government of India
- Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre
- Council of Scientific and Industrial Research, India
Zitieren
APA
Mishra, S. V., Banerjee, A., Sarkar, D., Thangarathnam, V., Bagal, B., Hasan, S. K., & Dutt, S. (2024). DNA-PKcs-mediated transcriptional regulation of TOP2B drives chemoresistance in acute myeloid leukemia. Journal of Cell Science. https://doi.org/10.1242/jcs.261931
Vancouver
Mishra SV, Banerjee A, Sarkar D, Thangarathnam V, Bagal B, Hasan SK, et al. DNA-PKcs-mediated transcriptional regulation of TOP2B drives chemoresistance in acute myeloid leukemia. Journal of Cell Science. 2024. doi:10.1242/jcs.261931
BibTeX
@article{Mishra2024,
author = {Mishra, Saket V and Banerjee, Archisman and Sarkar, Debashmita and Thangarathnam, Vishnuvarthan and Bagal, Bhausaheb and Hasan, Syed K and Dutt, Shilpee},
title = {DNA-PKcs-mediated transcriptional regulation of TOP2B drives chemoresistance in acute myeloid leukemia},
journal = {Journal of Cell Science},
year = {2024},
doi = {10.1242/jcs.261931}
}
EUVIMED